Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.45 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6423119 | 0.85 | PPARG (0.46) | CA12CA9CA2ALDH1A1LMNA | |
| SCHEMBL739191 | 0.85 | PPARG (0.58) | PPARGPPARDPPARAACLY | |
| SCHEMBL10569099 | 0.84 | CA12 (0.63) | CA12CA9CA2ALDH1A1LMNA | |
| SCHEMBL12496691 | 0.84 | PPARG (0.43) | CA12CA9CA2ALDH1A1LMNA | |
| SCHEMBL12496661 | 0.84 | PTGDR (0.42) | CA12CA9CA2ALDH1A1LMNA | |
| SCHEMBL12496645 | 0.81 | HTR6 (0.57) | HTR6MEN1KMT2ANOD1CXCL8 | |
| SCHEMBL21822231 | 0.81 | USP2 (0.42) | CA12CA9CA2ALDH1A1MAPT | |
| SCHEMBL11928530 | 0.81 | NOD1 (0.39) | CA12CA9CA2ALDH1A1LMNA | |
| SCHEMBL28204828 | 0.80 | CA12 (0.55) | CA12CA9CA2ALDH1A1LMNA | |
| SCHEMBL13236386 | 0.79 | CNR2 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012117216-A1 | N- (ARYLALKYL) - 1H- INDOLE- 2 - SULFONIC ACID AMIDE COMPOUNDS AND THEIR THERAPEUTIC USE AS CANNABINOID ALLOSTERIC MODULATORS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2012-09-07 | — | — | WO | disclosed |
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1346994-A1 | CHOLESTEROL BIOSYNTHESIS INHIBITORS CONTAINING AS THE ACTIVE INGREDIENT TRICYCLIC SPIRO COMPOUNDS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
| EP-0355827-B1 | Hydantoin derivatives | MOCHIDA PHARM CO LTD (JP) | 1997-01-02 | — | — | EP | disclosed |
| US-RE35279-E | ALDOSE REDUCTASE INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1996-06-18 | — | — | US | disclosed |
| US-5202339-A | Hypoglycemic, hypolipedemic agents | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1993-04-13 | — | — | US | disclosed |
| US-5004751-A | Antidiabetic agents; aldoe reductase inhibitors | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1991-04-02 | — | — | US | disclosed |
| US-4914099-A | TREATMENT OR PREVENTION OF DIABETIC COMPLICATIONS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1990-04-03 | — | — | US | disclosed |
| WO-1990002126-A1 | HYDANTOIN DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1990-03-08 | — | — | WO | disclosed |
| EP-0355827-A2 | Hydantoin derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1990-02-28 | — | — | EP | disclosed |
| US-4836846-A | PRE/POST EMERGENCE; WEEDS, GRASSES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-06-06 | — | — | US | disclosed |
| WO-1989001934-A1 | HYDANTOIN DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1989-03-09 | — | — | WO | disclosed |
| EP-0305947-A1 | Hydantoin derivatives, process for their preparation and pharmaceutical compositions containing the same as well as their use | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1989-03-08 | — | — | EP | disclosed |
| US-4764610-A | Herbicidal indole sulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-08-16 | — | — | US | disclosed |
| EP-0070698-B1 | HERBICIDAL INDOLE SULFONAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-11-13 | — | — | EP | disclosed |
| EP-0070698-A1 | Herbicidal indole sulfonamides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | CA12 3106/4885CA9 3719/4885CA2 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.